Phase II study of arsenic trioxide, ascorbic acid, dexamethasone, and thalidomide in patients with previously untreated high-risk or relapsed or refractory multiple myeloma
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Arsenic trioxide; Ascorbic acid; Dexamethasone; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- 10 Jul 2013 Biomarkers information updated
- 18 Aug 2005 New trial record.